
|Slideshows|December 6, 2014
Are We Overtreating DCIS?
Author(s)Laura J. Esserman, MD, MBA
With evidence from a number of studies, this presentation delves into the controversy surrounding the treatment, or overtreatment, of ductal carcinoma in situ (DCIS), and discusses whether or not these lesions should indeed be classified as breast cancer.
Advertisement
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer
2
Pirtobrutinib Monotherapy Earns Canadian Approval in Lymphoma/Leukemia Populations
3
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
4
FDA Receives NDA for Lirafugratinib in 2L FGR2-Mutated Cholangiocarcinoma
5


































